Cancer results from failures in epigenetic control by chromatin remodelers at the level of gene transcription. The abnormal activation of epithelial to mesenchymal transition (EMT) by carcinomas is an essential hallmark of cancer metastasis that is responsible for more than 90% of cancer deaths.
Our aim is to elucidate the orchestration of EMT-MET cascade by the balancing act of chromatin remodelers and epigenetic modifiers. It is anticipated that chromatin modifying compounds will emerge as the next generation of anticancer therapies.
Open to PhD applications in the fields of
Our dedicated hub for postgraduate students, providing state-of-the-art facilities for study, and high-quality training and development programmes within a diverse interdisciplinary community.The gateway to your postgraduate experience
Queen's University Belfast is committed to Equality, Diversity and Inclusion.
For more information please read our Equality and Diversity Policy.
Queen's University Belfast is registered with the Charity Commission for Northern Ireland NIC101788
VAT registration number: GB 254 7995 11